Evidence map›Paper›PMID 40081944›Full record

ArticleJournal for immunotherapy of cancer2025

Minglei Yang, Chenxi Zheng, Yu Miao, Cuicui Yin, Longfei Tang, Chongli Zhang, Pu Yu, Qingfang Han, Yihui Ma, Shenglei Li and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Journal for immunotherapy of cancer · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Minglei YangDepartment of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China yangmlei3@mail2.sysu.edu.cn xiapeiyi@sibcb.ac.cn liwencai@zzu.edu.cn guozhongjiang@zzu.edu.cn lslbljys@126.com.ORCID http://orcid.org/0000-0001-9957-7608
Chenxi ZhengThe Department of Dermatology, Henan Second Provincial People's Hospital, Zhengzhou, China.
Yu MiaoHenan Academy of Sciences, Zhengzhou, Henan, China.
Cuicui YinDepartment of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Longfei TangDepartment of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Chongli ZhangDepartment of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Pu YuDepartment of Oncology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Hennan, China.
Qingfang HanDepartment of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Yihui MaFirst Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Shenglei LiDepartment of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China yangmlei3@mail2.sysu.edu.cn xiapeiyi@sibcb.ac.cn liwencai@zzu.edu.cn guozhongjiang@zzu.edu.cn lslbljys@126.com.
Guozhong JiangDepartment of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China yangmlei3@mail2.sysu.edu.cn xiapeiyi@sibcb.ac.cn liwencai@zzu.edu.cn guozhongjiang@zzu.edu.cn lslbljys@126.com.
Wencai LiDepartment of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China yangmlei3@mail2.sysu.edu.cn xiapeiyi@sibcb.ac.cn liwencai@zzu.edu.cn guozhongjiang@zzu.edu.cn lslbljys@126.com.
Peiyi XiaDepartment of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China yangmlei3@mail2.sysu.edu.cn xiapeiyi@sibcb.ac.cn liwencai@zzu.edu.cn guozhongjiang@zzu.edu.cn lslbljys@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmune checkpoint blockade (ICB)-based immunotherapy has significantly improved survival in advanced melanoma. However, many patients exhibit resistance to these therapies. This study examines the impact of

methodsWe analyzed methylation and gene expression data from public datasets (The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO)) and an in-house cohort of melanoma patients treated with ICB therapy at the First Affiliated Hospital of Zhengzhou University. We developed a quantitative methylation-specific PCR (qMSP) assay to measure methylation levels of the cg24157392 and cg03995631 CpG sites, and a targeted bisulfite sequencing assay was used to validate the accuracy of qMSP. We measured BTLA protein expression using multiplex immunofluorescence and immunohistochemical staining methods. Pearson correlation, survival analysis, and immune cell infiltration estimation were conducted to explore the associations between

resultsHypomethylation at CpG sites cg24157392 and cg03995631 in the

conclusions

Indexed as

DNA MethylationImmunotherapyMelanomaPromoter Regions, GeneticReceptors, ImmunologicAgedBiomarkers, TumorFemaleHumansMaleMiddle AgedPrognosisBiomarkers, TumorBTLA protein, humanReceptors, ImmunologicBiomarkerImmune Checkpoint InhibitorSkin CancerTumor infiltrating lymphocyte - TILTumor microenvironment - TME

Identifiers

PMID40081944
PMCPMC11907004

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.